Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
The medical device registration application of Bonvadis for all indications of wounds has been accepted by Health Canada.
2025
2024
2023
2022
2021
2020
2019
2018
2017
Home
/
Latest News
/
2023
2023
Date
Title
2023-12-25
Oneness has submitted medical device registration application of Bonvadis for wound care to the Saudi Food and Drug Authority (SFDA) in Kingdom of Saudi Arabia.
>
2023-12-19
Oneness announces the information about the investor’s conference of 2023 Q4.
>
2023-12-13
Oneness Biotech Co., Ltd. receives an Indian patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).
>
2023-12-09
News-Oneness is the first pharmaceutical company in Taiwan has been selected for inclusion in the Dow Jones Sustainability Index
>
2023-12-07
Oneness Biotech Co., Ltd. receives a Brazilian patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).
>
2023-12-05
A U.S. patent titled ”METHODS FOR PREPARATION OF PLECTRANTHUS AMBOINICUS EXTRACTS” has been granted.
>
2023-12-04
Oneness Biotech Co., Ltd. receives a Japanese patent titled “TREATING IGE-MEDIATED ALLERGIC DISEASES” on FB825.
>
2023-11-30
Oneness announces the resolution of the Board of Directors on the Record Date of Capital Increase for the issuance of Restricted Employee Shares in 2023.
>
2023-11-29
An European patent titled “USE OF FLAVONOID COMPOUND IN PREPARATION OF COMPOSITION FOR HEALING WOUND” has been granted.
>
2023-11-13
News-Taiwan’s First Category 1.1 Natural Drug Approved for Market in China
>
2023-11-10
Oneness Biotech Co., Ltd. receives a Hong Kong patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).
>
2023-11-09
FESPIXON, the new drug in treatment of diabetic foot ulcers has been approved as Class 1.1 natural new drug by National Medical Products Administration (NMPA) in China
>
2023-11-09
The Company’s 2023Q3 consolidated financial statements have been approved by the Board of Directors
>
2023-10-25
Oneness has submitted medical device registration application of Bonvadis for wound care to the Thai Food and Drug Administration (Thai FDA) in Thailand.
>
2023-10-04
The board of directors of the Company approved removal of the noncompete clause for managers.
>
1
2
3
…
5
Next »
